Business Context and Reporting Period
This Form 8-K was filed by Histogenics Corporation (not Ocugen, Inc.) on December 8, 2014. The report details corporate governance actions taken in connection with the completion of the Company's initial public offering (IPO).
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. It is a current report focused solely on legal and corporate structure amendments.
Material Changes
- Corporate Charter: The Company filed a Sixth Amended and Restated Certificate of Incorporation with the Delaware Secretary of State.
- Bylaws: The Company adopted Amended and Restated Bylaws.
- Purpose: These amendments were approved by the Board of Directors to finalize the corporate structure required for the completion of the IPO.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, risk factors, or discussion of contingencies. It references the prospectus filed on December 3, 2014, for a summary of capital stock provisions.
Investor Verification Checklist
- Verify the exact terms of the Sixth Amended and Restated Certificate of Incorporation (Exhibit 3.1).
- Review the Amended and Restated Bylaws (Exhibit 3.2) for governance rules.
- Confirm the final capital structure details in the prospectus filed on December 3, 2014.
- Note that this filing contains no financial performance data; refer to the S-1 Registration Statement for financial history.